SCHEMBL283979

SCHEMBL283979

CC(NC(C)c1ccccc1)c1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.61
ACP3 P15309 2/20 0.55
CYP3A4 P08684 2/20 0.52
CYP2D6 P10635 2/20 0.52
CHRM2 P08172 1/20 0.52
HTR1A P08908 1/20 0.52
ADRA2A P08913 1/20 0.52
ADORA3 P0DMS8 1/20 0.52
CHRM1 P11229 1/20 0.52
SMPD1 P17405 1/20 0.52
DRD1 P21728 1/20 0.52
TBXA2R P21731 1/20 0.52
SLC6A2 P23975 1/20 0.52
SLC6A4 P31645 1/20 0.52
ADRA1A P35348 1/20 0.52
OPRM1 P35372 1/20 0.52
DRD3 P35462 1/20 0.52
CASR P41180 1/20 0.52
HTR2B P41595 1/20 0.52
SLC6A3 Q01959 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30763462 1.00 SIGMAR1 (0.61) SIGMAR1ACP3CYP3A4CYP2D6CHRM2
SCHEMBL3749295 1.00 SIGMAR1 (0.61) SIGMAR1ACP3CYP3A4CYP2D6CHRM2
SCHEMBL8437895 1.00 SIGMAR1 (0.61) SIGMAR1ACP3CYP3A4CYP2D6CHRM2
SCHEMBL1200137 1.00 SIGMAR1 (0.61) SIGMAR1ACP3CYP3A4CYP2D6CHRM2
Hydrochloric Acid SCHEMBL2469805 0.97 SIGMAR1 (0.59) SIGMAR1ACP3CYP3A4CYP2D6CHRM2
Hydrochloric Acid SCHEMBL607712 0.97 SIGMAR1 (0.59) SIGMAR1ACP3CYP3A4CYP2D6CHRM2
Hydrochloric Acid SCHEMBL3078151 0.97 SIGMAR1 (0.59) SIGMAR1ACP3CYP3A4CYP2D6CHRM2
SCHEMBL8433113 0.89 SIGMAR1 (0.57) SIGMAR1ACP3CYP3A4CYP2D6CHRM2
SCHEMBL278474 0.89 SIGMAR1 (0.57) SIGMAR1ACP3CYP3A4CYP2D6CHRM2
SCHEMBL8433689 0.89 SIGMAR1 (0.57) SIGMAR1ACP3CYP3A4CYP2D6CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 613 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120040461-A Spirobarbitudes compound, preparation method and application 北京工业大学 2025-05-27 CN claimed
CN-120040462-A Spiropyrazinone compound, preparation method and application 北京工业大学 2025-05-27 CN claimed
WO-2025089950-A1 PROCESS FOR REMOVING CO2 FROM GAS CARBONORO TECHNOLOGY B.V. (NL) 2025-05-01 WO claimed
CN-111193069-B Electrolyte for electrochemical device, method for preparing the same, and electrochemical device 三星电子株式会社 2024-11-01 CN claimed
EP-4274878-A1 BASIC ASHLESS ADDITIVES AND LUBRICATING COMPOSITIONS CONTAINING SAME The Lubrizol Corporation (US) 2023-11-15 EP claimed
CN-111032047-B Method for producing optically active compound 多特疗法-1公司 2023-10-27 CN claimed
CN-116813643-A Chiral oxo-bridged oxazolyl heterocyclic compound and preparation method thereof 北京工业大学 2023-09-29 CN claimed
US-11746180-B2 Catalysts for polyurethane foam polyol premixes containing halogenated olefin blowing agents HONEYWELL INTERNATIONAL INC. (US) 2023-09-05 US claimed
US-11643398-B2 Metallic salt containing anion having heterocyclic aromatic structure, method of preparing the metallic salt, and electrolyte and electrochemical device each including the metallic salt SAMSUNG ELECTRONICS CO., LTD. (KR) 2023-05-09 US claimed
EP-3657590-B1 METALLIC SALT CONTAINING ANION HAVING HETEROCYCLIC AROMATIC STRUCTURE, METHOD OF PREPARING THE SAME, AS WELL AS ELECTROLYTE AND ELECTROCHEMICAL DEVICE EACH INCLUDING THE METALLIC SALT SAMSUNG ELECTRONICS CO LTD (KR) 2023-04-26 EP claimed
US-20090069581-A1 PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2009-03-12 US claimed
WO-2008092939-A2 PROCESS FOR THE PREPARATION OF OPTICALLY PURE OMEPRAZOLE VIA SALT FORMATION WITH A CHIRAL AMINE OR TREATMENT WITH AN ENTIOMER CONVERTING ENZYME AND CHROMATOGRAPHIC SEPARATION KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO (SI) 2008-08-07 WO claimed
WO-2008015217-A1 SEPARATING CO2 FROM GAS MIXTURES Universität Dortmund (DE) 2008-02-07 WO claimed
US-6060617-A REACTING AN ALKALI METAL HYDRIDE AND ALKALI METAL AMIDES WITH A SUBSTITUTED AMINE IN AN ETHER SOLVENT IN ABSENCE OF AN ELECTRON CARRIER TO PRODUCE AN ALKALI METAL AMIDE FREE OF ORGANIC CONTAMINANTS FMC CORPORATION (US) 2000-05-09 US claimed
EP-0843682-A1 HIGH PURITY FORMULATIONS OF HIGHLY SUBSTITUTED LITHIUM AMIDE BASES FMC CORPORATION (US) 1998-05-27 EP claimed
US-5726308-A High purity formulations of highly substituted lithium amide bases FMC CORPORATION (US) 1998-03-10 US claimed
WO-1997006173-A1 HIGH PURITY FORMULATIONS OF HIGHLY SUBSTITUTED LITHIUM AMIDE BASES FMC CORPORATION (US) 1997-02-20 WO claimed
WO-1995020637-A2 HYDROCARBON OIL-AQUEOUS FUEL AND ADDITIVE COMPOSITIONS MEG S.N.C. DI SCOPELLITI SOFIA & C. (IT) 1995-08-03 WO claimed
US-4450114-A Process for production of sulfuric acid semiesters SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1984-05-22 US claimed
US-4351765-A Process for the production of compounds having in the molecule at least one β-sulfatoethyl-sulfone group and at least one sulfonic acid group SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1982-09-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11643398-B2 Metallic salt containing anion having heterocyclic aromatic structure, method of preparing the metallic salt, and electrolyte and electrochemical device each including the metallic salt NAP1L1, AGTR1, AP2A1 SIGMAR1 2649/4885ACP3 2342/4885CYP3A4 3889/4885
US-20090069581-A1 PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES CYP2B6, UGT1A6, CYP2A6 SIGMAR1 901/4885ACP3 3352/4885CYP3A4 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.